Tandem Diabetes Care Strategy and Business Model

Executive Overview

Tandem Diabetes Care is a medical-device company focused on insulin pumps, automated insulin delivery software, and the disposable supplies that keep those systems running. Founded in 2006 and headquartered in San Diego, California, Tandem competes in diabetes technology, a category where clinical outcomes, user experience, reimbursement access, and interoperability with continuous glucose monitoring systems all matter. Its core franchise has been the t:slim X2 insulin pump with Control-IQ technology, while the newer Tandem Mobi platform is designed to extend the portfolio into a smaller, more mobile form factor. Tandem sells primarily in the United States and has been expanding internationally through a mix of direct operations and distribution partners. Strategically, Tandem is not trying to be the lowest-cost pump maker. It is trying to win through software-enabled automation, attractive device design, compatibility with leading glucose sensors, and an installed base that drives recurring supplies revenue over time. In FY2024, Tandem reported revenue of about $940 million. That makes the company a hybrid of medtech hardware, recurring consumables, and increasingly connected digital therapy.

Tandem Diabetes Care at a Glance

Logo
Common name	Tandem Diabetes Care
Full legal name	Tandem Diabetes Care, Inc.
Headquarters	San Diego, California, United States
Ownership	Public company; no controlling shareholder publicly disclosed
Ticker	TNDM
Exchange	NASDAQ
Market Cap	$984.08M
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2006; initial commercialization of the t:slim platform in the early 2010s; initial public offering in 2013; Basal-IQ launch in 2018; Control-IQ launch in 2020; Capillary Biomedical acquisition in 2022; AMF Medical acquisition in 2023; Tandem Mobi launch in 2024
Industry or industries	Medical devices; diabetes technology; insulin delivery
Key products or services	Insulin pumps, automated insulin delivery algorithms, infusion sets, cartridges, connected diabetes apps and support services
Geographic footprint	Primarily United States, with expanding international presence through direct operations and distributor partners
Business segments as officially reported	One reportable segment
Company website	https://www.tandemdiabetes.com/

1. What Is the Strategy of Tandem Diabetes Care?

1. 1a. What is the winning aspiration of Tandem Diabetes Care?

   Based on Tandem’s public materials, the company’s winning aspiration is to make intensive insulin therapy easier, more automated, and less burdensome for people with diabetes, while building a durable and profitable diabetes-technology platform. In practical terms, winning means becoming a preferred insulin-pump ecosystem for insulin-intensive users, expanding the installed base, generating recurring supplies revenue, and translating product innovation into sustained revenue growth and improving profitability. Tandem’s public messaging in FY2024 and into 2025 centered on reaccelerating growth through new products while also improving margins and operating discipline.

2. 1b. Where does Tandem Diabetes Care play?

   Tandem plays in insulin delivery for people who require intensive insulin therapy, especially those with type 1 diabetes and selected type 2 users for whom pump therapy is appropriate. It focuses on pumps, automated insulin delivery software, connected data tools, and the recurring consumables used with those pumps. It does not broadly compete across all diabetes devices; instead, it participates in a narrower part of the ecosystem and relies on interoperability with external continuous glucose monitoring, or CGM, platforms rather than building its own sensor. Geographically, the United States is the core market, with targeted expansion into international markets where reimbursement, clinical adoption, and channel economics support pump use.

3. 1c. How does Tandem Diabetes Care plan to win?

   Tandem’s path to winning is differentiation, not cost leadership. Its formula is a combination of user-friendly hardware, software-driven automated insulin delivery through Control-IQ, compatibility with leading CGM systems, and a connected experience that includes mobile tools and remote software updatability. That matters because pump users and prescribers care about therapy outcomes, ease of use, training burden, size and wearability, and confidence that the platform will keep improving over time. Tandem is also trying to win by offering choice across form factors, from the established t:slim X2 to the smaller Tandem Mobi platform.

4. 1d. What capabilities must Tandem Diabetes Care have in place?

   To execute this strategy, Tandem needs strong capabilities in regulated product development, algorithm design, human-factors engineering, mobile and connected software, CGM interoperability, clinical evidence generation, reimbursement support, and high-reliability manufacturing. It also needs a support model that can help patients and clinics navigate documentation, training, onboarding, and ongoing therapy management. In this market, a pump maker is not only designing hardware; it is managing a tightly regulated therapy ecosystem.

5. 1e. What management systems does Tandem Diabetes Care require?

   Tandem requires management systems built around quality, compliance, and lifecycle execution. That includes formal quality systems for a regulated medical device business, post-market surveillance, software release governance, clinical and regulatory program management, supplier qualification, complaint handling, and traceability. Commercially, it needs disciplined systems for reimbursement, installed-base management, renewals, and supplies replenishment. Financially, it needs close control of gross margin, operating expenses, inventory, and cash because growth in this business can consume working capital if launches and supply-chain planning are not tightly managed.

2. What Are the Current Strategic Initiatives of Tandem Diabetes Care?

Scale the Tandem Mobi launch

A central initiative in FY2024 and into 2025 has been commercializing Tandem Mobi in the United States. This matters strategically because Mobi gives Tandem a smaller, more mobile platform that can appeal to users who want more discretion and smartphone-centric control. Launch execution includes reimbursement expansion, clinician training, field support, manufacturing scale-up, and ensuring a reliable customer onboarding experience.

Broaden interoperability and keep the installed base current

Tandem has continued to emphasize sensor interoperability and software-enabled upgrades. Public materials have highlighted work with major CGM ecosystem partners, including Dexcom and Abbott. The strategic logic is clear: broader compatibility widens the addressable market, reduces switching friction, and helps Tandem keep existing users inside its ecosystem rather than forcing a hardware replacement every time the external sensor landscape evolves.

Expand international revenue

International growth remains a recurring priority in Tandem’s public communications. The company has been extending its reach through direct and distributor channels outside the United States, using automated insulin delivery capabilities as a key differentiator. International expansion is attractive because pump penetration and reimbursement structures vary by country, leaving room for growth if Tandem can localize market access, training, and channel execution.

Advance the pipeline beyond the current core pump portfolio

Tandem has been investing in next-generation offerings beyond the current installed base, including work related to patch-pump capabilities and infusion-set innovation. The AMF Medical acquisition added a patch-pump platform, while the Capillary Biomedical acquisition added extended-wear infusion-set technology. Together, these programs suggest that Tandem is trying to broaden its future product architecture, not just refresh the existing t:slim line.

Improve profitability and operating discipline

Alongside growth initiatives, management has publicly emphasized gross-margin improvement, spending discipline, and a more efficient operating model. For Tandem, that means better manufacturing scale, better supplies mix, more disciplined commercial spending, and tighter working-capital management. In a medtech business with recurring consumables but meaningful launch costs, execution on margins can materially affect strategic flexibility.

3. What Is the Business Model of Tandem Diabetes Care?

Tandem’s business model is best understood as a durable medical device placement model with a recurring consumables stream. It is not a pure subscription business, but it also is not a one-time hardware sale.

• What customers actually buy: Patients and providers buy insulin-pump systems, automated insulin delivery capabilities, infusion sets, cartridges, software connectivity, and the service and training needed to use the system safely.
• Recurring versus one-time revenue: Pump hardware is episodic. By contrast, infusion sets and cartridges are repeat purchases for as long as a patient remains on the platform. In addition, many users replace or upgrade pumps on a multiyear cycle, creating a renewal dynamic beyond the initial sale.
• Revenue model: The model combines upfront pump revenue, deferred warranty elements, and ongoing supplies revenue. In many cases, reimbursement pathways and channel arrangements matter as much as list prices.
• Pricing power: Pricing power exists, but it is constrained by reimbursement, competitive alternatives, and payer negotiations. Tandem’s differentiation on automation, usability, and sensor compatibility gives it more room than a commodity hardware maker would have, but this is not an unconstrained pricing environment.
• Why the business mix matters: A larger installed base usually improves visibility because each active user can generate recurring supplies demand. Supplies also tend to be strategically important to margin quality. A mix shift toward new hardware launches, distributor-heavy markets, or promotional activity can pressure margins in the short run even if it helps long-term installed-base growth.
• What drives gross margin, operating margin, and cash generation: Gross margin is shaped by component costs, manufacturing yields, warranty expense, mix between pumps and supplies, and channel mix. Operating margin depends heavily on research and development, sales and marketing, clinical support, and general administrative overhead. Cash generation depends on scale, working capital, reimbursement collections, and inventory control.

4. What Products and/or Services Does Tandem Diabetes Care Sell?

• t:slim X2 insulin pump: Tandem’s established flagship durable pump platform. It has been strategically important because it built the installed base that supports recurring supplies revenue and software-enabled upgrades.
• Tandem Mobi: A newer, smaller pump platform launched in 2024 in the United States. It is important as a growth product because it gives Tandem a more compact option in response to user demand for convenience and discretion.
• Control-IQ technology: Tandem’s automated insulin delivery algorithm and one of the company’s most important differentiators. It is central to the customer value proposition because it affects therapy automation, user experience, and clinical outcomes.
• Basal-IQ technology: An earlier algorithmic feature set focused on low-glucose suspend functionality. It remains part of Tandem’s technology portfolio, though Control-IQ has greater strategic importance.
• Infusion sets and cartridges: The consumables required to use Tandem pumps. These are economically important because they are repeat-purchase items tied to the installed base.
• Connected software and data tools: Tandem’s apps and data-management tools support setup, monitoring, and patient engagement. While they are not usually billed as standalone software subscriptions, they reinforce retention and clinical utility.
• Training and customer support: In practice, Tandem also sells a support experience. Onboarding, reimbursement guidance, clinical support, and ongoing service are part of how pump companies win and retain patients.

In FY2024, the legacy t:slim X2 base likely remained the largest revenue foundation, while Tandem Mobi represented the most important new growth offering. Strategically, however, Control-IQ and recurring supplies are at least as important as the pump hardware itself because they help define retention, economics, and competitive position.

5. What Are the Key Competitors or Peers of Tandem Diabetes Care?

Dexcom and Abbott are strategically important to Tandem, but they are better understood as ecosystem partners in CGM interoperability than as direct pump competitors.

6. What Is the Marketing Strategy of Tandem Diabetes Care?

Tandem’s marketing appears to be education-led and clinically grounded rather than mass-market in style. Because insulin pumps are reimbursed medical devices used in a regulated care pathway, brand awareness matters, but it is not enough by itself. The company needs to influence patients, prescribers, diabetes educators, caregivers, and payers.

• Provider and clinic marketing: Endocrinology practices, diabetes clinics, and certified educators are central gatekeepers. Clinical evidence, workflow support, and ease of training matter.
• Patient-oriented demand generation: Tandem appears to use digital channels, community engagement, and product positioning around ease of use, automation, and mobility to attract prospective pump users and switchers.
• Field and conference presence: Diabetes conferences and specialist events are important venues for product education and professional credibility.
• Reimbursement support as marketing: In this category, helping patients navigate coverage can be as important as promotional messaging. Reimbursement support is effectively part of the go-to-market model.

Marketing appears to be a supporting capability rather than Tandem’s primary moat. The stronger differentiators are product design, algorithm performance, CGM compatibility, and the service experience that makes therapy adoption less difficult.

7. What Are the Key Customer Segments of Tandem Diabetes Care?

• People with type 1 diabetes: This is Tandem’s core end market and the natural center of pump adoption.
• Insulin-intensive people with type 2 diabetes: A meaningful expansion opportunity, though adoption depends on reimbursement, clinician behavior, and evidence of value relative to other therapy approaches.
• Pediatric users and caregivers: Children, adolescents, and their caregivers are important because automation, alerts, and ease of use can materially reduce disease-management burden.
• Adult pump switchers: Users changing from a rival pump or moving from injections to pump therapy are an important commercial segment.
• Prescribers and diabetes-care teams: These clinicians are not the end users, but they are crucial decision influencers and operational gatekeepers.
• Payers and reimbursement intermediaries: Commercial insurers, government programs, durable medical equipment channels, and pharmacy-benefit pathways shape access and economics.
• International distributors and provider partners: Outside the United States, channel partners are often essential for market access, training, and local execution.

Tandem is not broadly diversified across unrelated end markets. It is concentrated in insulin-intensive diabetes, which creates focus but also means reimbursement, clinical adoption, and product execution in that niche matter disproportionately.

8. What Is the Sales Model of Tandem Diabetes Care?

In the United States, Tandem’s sales model appears to combine direct commercial coverage, reimbursement support, clinical onboarding, and ongoing customer service. Selling a pump is not simply a transactional device sale. It typically involves prescription workflow, payer approval, documentation, patient training, and follow-up support.

• Direct U.S. commercial model: Tandem works with patients, clinicians, and payers through a direct sales and support structure.
• Recurring supplies model: After the initial pump placement, ongoing supplies are reordered on a repeat basis, giving the company continuing touchpoints with the user base.
• International distributor and direct-market mix: Outside the United States, Tandem uses a combination of direct presence and third-party distribution depending on market scale and reimbursement structure.
• Digital support layer: Apps, data tools, and remote software management support retention and therapy continuity, even when they are not separately monetized.

The channel structure affects economics. Direct selling provides more customer intimacy and potentially better long-term value capture, but it also requires more operating expense. Distributor channels can expand reach faster in smaller international markets, but some economics are shared with partners. In Tandem’s case, sales effectiveness depends as much on reimbursement execution and clinical support as on traditional quota-carrying sales activity.

9. In What Geographies Does Tandem Diabetes Care Operate?

Tandem’s business is centered in the United States, which remains its largest commercial market and the core of its reimbursement, training, and service infrastructure. The company’s headquarters and primary corporate functions are in San Diego, California.

Internationally, Tandem has been building a broader presence through a mix of direct operations and distributor partners. Public materials indicate an expanding footprint across markets including Canada, Europe, Australia, New Zealand, and selected other countries. The exact channel mix varies by market, reflecting differences in reimbursement systems, clinical practice, and local scale.

Operationally, Tandem’s footprint is more concentrated than that of a global diversified medtech company. Its customers are spread across multiple regions, but the company remains U.S.-weighted in commercial importance. Manufacturing, fulfillment, and supply activities rely on a combination of internal capabilities and qualified third-party partners, which allows international reach without requiring a fully localized manufacturing base in every country.

10. Who Are the Owners of Tandem Diabetes Care?

Tandem Diabetes Care is a publicly traded company, and ownership is dispersed. No controlling shareholder is publicly disclosed. Based on recent SEC filings and proxy disclosures, large institutional holders have included firms such as BlackRock, The Vanguard Group, and State Street. As is typical for a mid-cap public medtech company, ownership is primarily institutional rather than founder- or family-controlled.

11. How Is Tandem Diabetes Care Organized?

Officially, Tandem reports one reportable segment. That is important because it means the company manages the business as an integrated diabetes-device platform rather than as a portfolio of unrelated divisions.

Practically, the company appears to be organized around a functional operating model with product-platform overlay:

• Commercial functions: U.S. and international sales, market access, reimbursement support, and customer service.
• Research and development: Pump hardware, algorithms, mobile software, connectivity, and future product pipeline.
• Clinical, regulatory, and quality: Clinical evidence generation, regulatory submissions, post-market surveillance, and quality systems.
• Operations and supply chain: Procurement, manufacturing coordination, inventory, fulfillment, and supplier management.
• Corporate functions: Finance, legal, human resources, and information technology.

This structure fits a business where success depends on tightly linking product development, regulation, manufacturing, reimbursement, and long-term patient support.

12. How Does Tandem Diabetes Care Operate?

Tandem operates as a regulated therapy-platform company. Day to day, value creation comes from designing pump systems and algorithms, getting them cleared by regulators, producing reliable devices and supplies, helping users get reimbursed and trained, and then supporting those users over the life of the therapy.

1. Design and develop the platform: Tandem develops pump hardware, control algorithms, software, connectivity, and associated consumables.
2. Validate and regulate: Products must pass through clinical, quality, and regulatory processes before launch and throughout their commercial life.
3. Source, build, test, and release: Components and subassemblies are procured, devices and consumables are manufactured or assembled through internal and partner networks, and products are tested under strict quality controls.
4. Reimburse, ship, and onboard: Pumps move through documentation, insurance approval, shipment, setup, and patient training.
5. Support the installed base: Tandem replenishes supplies, provides technical and clinical support, manages software updates where applicable, and monitors product quality and complaints.

The main operational complexities are reimbursement friction, supplier qualification, launch execution, software and hardware reliability, and the fact that therapy interruption can have clinical consequences. That makes service levels, traceability, and quality management especially important.

13. What Are the Growth Opportunities for Tandem Diabetes Care?

• Expanding penetration in type 1 diabetes: Even within Tandem’s core market, there is room to win new starts and switches from competing systems or from injections.
• Broadening into insulin-intensive type 2 diabetes: This is a plausible growth opportunity if evidence, indications, and reimbursement continue to improve.
• Scaling Tandem Mobi: A smaller form factor can help Tandem reach users who may not have preferred a traditional pump design.
• International expansion: Markets outside the United States can add growth if Tandem can build reimbursement access and effective local channel execution.
• Installed-base monetization: More active users drive more recurring infusion-set and cartridge demand, and over time they create a renewal pool for future hardware cycles.
• Sensor interoperability and ecosystem breadth: Wider CGM compatibility can expand the addressable market and reduce customer attrition.
• Pipeline adjacencies: Patch-pump technology, infusion-set innovation, and broader software functionality can open new growth paths beyond the current portfolio.

The main constraints are competition from larger and well-funded rivals, reimbursement pressure, product-launch execution risk, regulatory timing, and the need to maintain a reliable supply chain while introducing new platforms.

14. What Is the History of Tandem Diabetes Care?

• 2006: Tandem was founded in San Diego by medtech entrepreneurs, with Kim Blickenstaff widely associated with the company’s founding and early development.
• Early years: The company focused on bringing a differentiated touchscreen insulin-pump experience to market, helping distinguish it from more utilitarian legacy pump designs.
• 2013: Tandem completed its initial public offering and became a public company.
• Mid-2010s: The company went through a difficult period marked by losses and liquidity pressure, underscoring how hard it is to scale a medical-device platform in a reimbursement-heavy market.
• 2018: Tandem launched Basal-IQ, an important step toward more automated therapy.
• 2020: Control-IQ became a major milestone, strengthening Tandem’s competitive position in automated insulin delivery.
• 2022: Tandem acquired Capillary Biomedical to add infusion-set technology capabilities.
• 2023: Tandem acquired AMF Medical, adding a patch-pump platform that could matter for the future product roadmap.
• 2024: Tandem launched Tandem Mobi in the United States, marking a significant new product cycle.

The broad historical arc is a move from a niche pump entrant to a software-enabled diabetes-technology platform with a larger installed base, wider automation capabilities, and a more diversified future pipeline.

15. What Are the Key Suppliers to Tandem Diabetes Care?

Suppliers matter materially to Tandem because it sells regulated medical devices and therapy-critical consumables. Public disclosures indicate dependence on qualified suppliers, and in some cases single-source or limited-source arrangements are a meaningful operational risk.

• Electronic and electromechanical component suppliers: Pumps depend on specialized components that must meet strict performance and regulatory standards.
• Disposable plastics and consumables suppliers: Infusion sets, cartridges, and related components are essential to the recurring-revenue model.
• Contract manufacturing and specialized process partners: Certain manufacturing, assembly, or sterilization activities may be handled by external partners that must be validated and monitored.
• Logistics and fulfillment providers: Reliable delivery matters because users need uninterrupted access to supplies.
• Strategic ecosystem partners: Companies such as Dexcom and Abbott are not typical component suppliers, but their interoperability role is strategically important because Tandem’s value proposition depends in part on sensor compatibility.

Supplier structure matters because switching suppliers in medical devices is not quick. Qualification, testing, regulatory documentation, and quality validation can make supply disruptions expensive and slow to solve.

16. What Are the Key Brands Owned by Tandem Diabetes Care?

Branding matters at Tandem, though more as a shorthand for therapy experience and technology architecture than as a classic consumer-goods brand strategy.

• t:slim X2: The company’s established flagship pump brand and the core of its installed base.
• Tandem Mobi: Tandem’s newer compact pump brand, positioned around mobility and a smaller wearable footprint.
• Control-IQ: The most strategically important software brand in the portfolio, associated with automated insulin delivery.
• Basal-IQ: An earlier automation feature brand focused on low-glucose suspend functionality.
• t:connect: Tandem’s connected software and data-management layer, supporting the digital experience around pump use.

In this market, the strongest brands are the ones tied to clinical outcomes, ease of use, and ecosystem trust. That makes Control-IQ and the core pump platforms more important than a broad house-of-brands approach.

17. How Does the Supply Chain of Tandem Diabetes Care Function?

Tandem’s supply chain supports both a durable device business and a recurring consumables business. That combination creates a different operating challenge than a one-time capital-equipment model.

1. Sourcing: Tandem procures specialized components and materials from qualified suppliers, some of which may be limited-source.
2. Manufacturing and assembly: Pumps and consumables are produced through a mix of internal processes and qualified external partners, with quality controls embedded throughout.
3. Inventory and release: Finished goods must be managed carefully because pumps are higher-value devices while supplies are repeat-demand items with service-level implications.
4. Distribution and delivery: Initial pumps move through reimbursement-linked fulfillment, while supplies require reliable recurring delivery to active users.
5. Returns, complaints, and traceability: Because these are regulated products used in ongoing therapy, post-market traceability and complaint handling are integral parts of the supply chain.

Supply-chain reliability is strategically important because users cannot easily tolerate gaps in therapy. Cost matters, but continuity, compliance, and product quality matter just as much.

18. What Is the Technology Strategy of Tandem Diabetes Care?

Tandem’s technology strategy is central to competitiveness. The company is not just making pumps; it is building a connected insulin-delivery platform in which hardware, algorithms, mobile software, and third-party sensor interoperability work together.

• Software-enabled therapy: Control-IQ shows that software and dosing logic are core to the value proposition, not an accessory.
• Interoperable ecosystem design: Tandem’s strategy has favored compatibility with leading CGMs rather than vertical integration into sensor manufacturing.
• Remote updatability and lifecycle extension: Software-update capability can extend the useful commercial life of the installed base and improve retention.
• Miniaturization and mobility: Tandem Mobi reflects a technology push toward smaller, more flexible hardware and greater smartphone-centric control.
• Connected data layer: Apps and data tools support patient engagement, clinician visibility, and a stickier ecosystem.
• Cybersecurity and quality systems: In a connected medical-device business, technology strategy also includes secure software development and regulated change control.

Technology at Tandem is both an internal enabler and part of the customer offering. That is why engineering execution, software quality, and interoperability partnerships are so important to strategic position.

19. What Is the R&D Strategy of Tandem Diabetes Care?

Research and development is a major strategic function for Tandem. The company’s growth case depends heavily on continuing to improve hardware, algorithms, consumables, and connected features in a market where product cycles drive share shifts.

• Core platform enhancement: Ongoing work to improve pump usability, size, reliability, and software capability.
• Automated insulin delivery advancement: Continued refinement of Control-IQ and related algorithmic functionality, including broader use cases where supported by evidence and regulatory clearance.
• Consumables innovation: Infusion-set development is important because wear duration, comfort, reliability, and ease of use affect both outcomes and retention.
• Next-generation form factors: Patch-pump and miniaturized designs broaden the future product roadmap.
• Clinical and human-factors work: Because these are therapy devices, R&D includes not only engineering but also clinical validation, usability testing, and regulatory preparation.

The Capillary Biomedical and AMF Medical acquisitions suggest that Tandem’s R&D strategy is not limited to internal invention. It is also willing to acquire technologies that accelerate roadmap development in areas adjacent to the core pump franchise.

20. What Is the Finance Strategy of Tandem Diabetes Care?

Tandem’s finance strategy in FY2024 and into 2025 appears centered on balancing growth investment with a more disciplined path toward profitability. This is typical for a medtech platform that has meaningful R&D and commercial needs but also needs to protect liquidity.

• Reinvest behind growth: Capital is directed primarily toward product launches, R&D, market expansion, and commercial infrastructure rather than dividends.
• Improve gross margin: Mix, scale, supply-chain execution, and manufacturing efficiency are key levers.
• Manage operating expense growth: Launches require investment, but public messaging has emphasized more disciplined spending and better operating leverage.
• Protect working capital: Inventory planning and reimbursement collections matter because hardware launches and supplies availability can tie up cash.
• Maintain strategic flexibility: A healthier margin and cash profile gives Tandem more room to fund pipeline development and absorb competitive pressure.

In short, Tandem’s finance strategy is not about maximizing near-term cash extraction. It is about funding innovation and commercial execution while moving the model toward more durable profitability.

21. What Major Acquisitions Has Tandem Diabetes Care Made?

Tandem does not appear to be a serial roll-up acquirer. Its deal activity has been selective and capability-driven.

The pattern suggests Tandem uses acquisitions to fill technology gaps, accelerate platform evolution, and create future options, not to assemble a conglomerate of unrelated assets.

22. How Companies Like Tandem Diabetes Care Leverage Independent Consultants through Umbrex

Umbrex has built a global community of more than 8,000 independent management consultants based in over 50 countries. These consultants are alumni of McKinsey, Bain, BCG, and other top firms. Companies like Tandem Diabetes Care engage Umbrex when they want the training and problem-solving approach of top-tier consulting talent but do not need a full consulting team with the related overhead. Umbrex consultants work across Strategy, Operations, Organization, Marketing, Sales, Finance, Technology, ERP, and AI. For a company like Tandem, the most relevant projects are usually the ones tied to commercialization, market access, supply chain, product pipeline execution, and operating-model improvement.

• U.S. launch acceleration support for Tandem Mobi, including launch metrics, field feedback loops, and commercialization PMO design.
• International market prioritization and channel strategy for new-country expansion, including distributor economics and reimbursement readiness assessments.
• Installed-base retention and renewal analytics to reduce churn and improve conversion from legacy users into newer Tandem platforms.
• Gross-margin improvement work across procurement, manufacturing, warranty cost, and supplies mix.
• Market access and reimbursement strategy for broader patient populations, including type 2 opportunity assessment and payer-value messaging.
• Sales-force and clinical-support coverage redesign to improve productivity across endocrinology clinics, diabetes educators, and patient onboarding workflows.
• End-to-end supply-chain and sales-and-operations planning improvement for pumps and consumables, with a focus on service levels and working capital.
• Commercialization strategy for next-generation products such as patch-pump platforms or improved infusion-set offerings.
• Post-acquisition integration support for acquired technologies, helping translate capabilities from deals such as AMF Medical and Capillary Biomedical into an executable roadmap.
• Digital transformation projects spanning CRM, ERP, service operations, forecasting, and targeted AI use cases in customer support, demand planning, or quality analytics.